Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2018-03-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
6-K Filing
Regulatory Filings
2018-03-01 English
Lynparza CHMP for ovarian cancer maintainance
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated February 23, 2018. It announces a positive opinion from the EU CHMP regarding the drug Lynparza. The content is a press release detailing clinical trial results and regulatory progress, which is typical of a company making a material announcement to the market. Since it is a formal announcement disseminated via the London Stock Exchange's news service (RNS), and it is not a full financial report (like 10-K or IR), nor a specific management change or dividend notice, the most appropriate classification is the general regulatory announcement category, RNS. It is not an Earnings Release (ER) as it focuses on drug approval/opinion, not period financial results.
2018-02-23 English
6-K Filing
Regulatory Filings
2018-02-23 English
6-K Filing
Regulatory Filings
2018-02-20 English
AstraZeneca's IMFINZI approved for Stage III nsclc
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content is a press release announcing the US FDA approval of a drug (Imfinzi) and provides key clinical data and quotes. This type of announcement, which is a formal regulatory disclosure but not a comprehensive periodic report (like 10-K or IR) or a specific shareholder communication (like DEF 14A), fits best under the general regulatory filing category. Since it is a formal, time-sensitive announcement distributed through the official channel (RNS), and it doesn't fit the specific definitions for ER (Earnings Release), CAP (Financing), or DIV (Dividend), the most appropriate classification is RNS (Regulatory Filings) as the general fallback for official regulatory disclosures.
2018-02-19 English
Selumetinib in NF1 gets FDA orphan drug status
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 9694E' and is dated 15 February 2018. The content is an announcement regarding the US FDA granting Orphan Drug Designation (ODD) for selumetinib for NF1 treatment. This format—a brief, time-sensitive announcement disseminated via the RNS service (London Stock Exchange's company news service)—is characteristic of a general regulatory filing or news release that doesn't fit a more specific financial report category (like 10-K, ER, or IR). Since it is a formal announcement of a regulatory/clinical event distributed through the official channel, the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for such announcements.
2018-02-15 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.